ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 37 for:    lyme AND Antibiotics

Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00138801
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : February 5, 2010
Sponsor:
Information provided by:
Sorlandet Hospital HF

Brief Summary:
The aim of this study is to compare parenteral ceftriaxone and oral doxycycline in the treatment of neuroborreliosis in a randomized controlled trial.

Condition or disease Intervention/treatment Phase
Lyme Neuroborreliosis Drug: Ceftriaxone Drug: Doxycycline Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison
Study Start Date : March 2004
Actual Primary Completion Date : March 2008
Actual Study Completion Date : December 2008






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Neurological symptoms and/or findings consistent with neuroborreliosis and at least one of the following fulfilled:

    • Intrathecal production of borrelia antibodies;
    • White cell count in cerebrospinal fluid (CSF) > 5/mm3;
    • Significant rise in borrelia antibodies in two serum samples collected from a patient with at least 3 weeks interval;
    • Verified acrodermatitis chronica atrophicans.

Exclusion Criteria:

  • Allergy to the contents in the medication, or earlier type I reaction to penicillin.
  • Treatment with cephalosporins, penicillin or tetracyclins during the last 14 days
  • Pregnancy or breastfeeding
  • Age < 18 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00138801


Locations
Norway
Sørlandet Sykehus HF
Kristiansand, Vest-Agder, Norway, 4633
Sponsors and Collaborators
Sorlandet Hospital HF
Investigators
Study Chair: Åse Mygland, MD, PhD Sorlandet Sykehus HF

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Svein Gunnar Gundersen, Sorlandet hospital HF
ClinicalTrials.gov Identifier: NCT00138801     History of Changes
Other Study ID Numbers: SSHF813204
First Posted: August 30, 2005    Key Record Dates
Last Update Posted: February 5, 2010
Last Verified: March 2005

Keywords provided by Sorlandet Hospital HF:
Neuroborreliosis

Additional relevant MeSH terms:
Lyme Neuroborreliosis
Lyme Disease
Anti-Bacterial Agents
Central Nervous System Bacterial Infections
Bacterial Infections
Borrelia Infections
Gram-Negative Bacterial Infections
Tick-Borne Diseases
Spirochaetales Infections
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Doxycycline
Ceftriaxone
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents